POSTSURGICAL SURVEILLANCE OF PATIENTS WITH FIGO STAGE I/II ENDOMETRIAL ADENOCARCINOMA

被引:84
|
作者
BERCHUCK, A
ANSPACH, C
EVANS, AC
SOPER, JT
RODRIGUEZ, GC
DODGE, R
ROBBOY, S
CLARKEPEARSON, DL
机构
[1] DUKE UNIV, DEPT PATHOL, DURHAM, NC 27710 USA
[2] DUKE UNIV, DEPT BIOSTAT, CTR CANC, DURHAM, NC 27710 USA
关键词
D O I
10.1006/gyno.1995.1262
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To examine the effect of postsurgical surveillance on survival of patients with FIGO stage I/II endometrial adenocaricinoma. Methods: We examined the records of 354 patients who underwent primary surgical therapy for FIGO stage I/II endometrial adenocarcinoma. In patients who developed recurrent disease, we determined whether symptoms or signs of disease were present at recurrence and whether there was evidence of disease on Pap smear or chest radiograph. Results: Among the 354 patients in this study, 44 (12%) developed recurrent disease. Sites of recurrence included 12 (27%) isolated vaginal, 12 (27%) pelvis with vagina or abdomen, 4 (10%) isolated lung, 13 (29%) pelvic/abdominal with other distant sites, and 3 (7%) other distant sites. At diagnosis of recurrence 61% of patients had symptoms related to their cancer, 68% had physical exam findings suggestive of recurrence, and 84% had symptoms and/or signs. Findings consistent with recurrent cancer were detected by Pap smear in 25% and on chest radiograph in 20%. Among the 44 patients who developed recurrent disease, 8 (18%) remain alive without evidence of disease, including 6/12 (50%) with isolated vaginal disease and 2/34 (6%) with other patterns of recurrent disease (P = 0.01). Among the 12 patients with isolated vaginal recurrence, 1/3 (33%) in whom recurrent disease was diagnosed by Pap smear alone was salvaged compared to 5/9 (56%) who had symptoms or signs of vaginal recurrence. None of the three patients in whom an abnormal chest radiograph was the only evidence of recurrence survived. Conclusions: Because of the low recurrence rate of FIGO stage I/II endometrial cancer and the paucity of effective second-line treatment, surveillance Pap smears and chest radiographs appear to have little impact on survival. Although few asymptomatic potentially curable recurrences were detected due to surveillance examinations, the value of psychological reassurance associated with a normal examination is difficult to quantitate. (C) 1995 Academic Press, Inc.
引用
收藏
页码:20 / 24
页数:5
相关论文
共 50 条
  • [1] A metabolomic signature of FIGO stage I and II endometrial cancer
    Gu, Mingli
    Chen, Xin
    Sun, Yi
    Wan, Linguo
    Shu, Huizhen
    Qian, Cheng
    [J]. NEOPLASMA, 2021, 68 (06) : 1283 - +
  • [2] Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients
    Kalogiannidis, I.
    Lambrechts, S.
    Amant, F.
    Neven, P.
    Van Limbergen, E.
    Vergote, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (05) : 1885 - 1893
  • [3] Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy
    Cahan, Benjamin
    Kim, Ji Hyun
    Schultheiss, Timothy E.
    Wong, Jeffrey Y. C.
    Chen, Yi-Jen
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 302 - 306
  • [4] Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy
    Kim, J. H.
    Schultheiss, T. E.
    Wong, J. Y.
    Chen, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S96 - S97
  • [5] Preoperative radiotherapy in stage I/II endometrial adenocarcinoma
    Maingon, P
    Horiot, JC
    Fraisse, J
    Salas, S
    Collin, F
    BoneLepinoy, MC
    Barillot, I
    Douvier, S
    Padeano, MM
    Cuisenier, J
    [J]. RADIOTHERAPY AND ONCOLOGY, 1996, 39 (03) : 201 - 208
  • [6] Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma
    Nasioudis, Dimitrios
    Mastroyannis, Spyridon A.
    Ko, Emily M.
    Haggerty, Ashley F.
    Cory, Lori
    Giuntoli, Robert L., II
    Kim, Sarah H.
    Latif, Nawar A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (11) : 1355 - 1360
  • [7] Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma
    Nasioudis, Dimitrios
    Byrne, Maureen
    Mastroyannis, Spyridon
    Ko, Emily
    Haggerty, Ashley
    Latif, Nawar
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S270 - S270
  • [8] Analysis of Patients with 1988 FIGO Stage-II Endometrial Cancer
    Ureyen, Isin
    Turan, Taner
    Kimyon, Gunsu
    Karalok, Alper
    Tasci, Tolga
    Boran, Nurettin
    Tulunay, Gokhan
    Kose, M. Faruk
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2014, 24 (04): : 239 - 246
  • [9] Prognostic factors for recurrence in patients with FIGO stage I and II, intermediate or high risk endometrial cancer
    Zusterzeel, P. L. M.
    Bekkers, R. L. M.
    Hendriks, J. C. M.
    Neesham, D. N.
    Rome, R. M.
    Quinn, M. A.
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2008, 87 (02) : 240 - 246
  • [10] A suggested modification to FIGO stage I endometrial cancer
    Aristizabal, Patrick
    Graesslin, Olivier
    Barranger, Emmanuel
    Clavel-Chapelon, Francoise
    Haddad, Bassam
    Luton, Dominique
    Darai, Emile
    Rouzier, Roman
    Koskas, Martin
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 192 - 196